Bottom line
In 2026, about 60% of commercially insured Americans have some GLP-1 coverage for obesity. Medicare Part D does not cover anti-obesity drugs but does cover Wegovy for its cardiovascular risk indication in patients with established heart disease. State Medicaid coverage varies from "fully covered" to "not covered at all." Employers remain the single biggest determinant of whether your insurance will pay.
If you have commercial insurance, your cheapest path is almost always to work through coverage + savings card, not around it. If you have Medicare or live in a non-coverage state, cash programs and manufacturer direct channels typically beat insurance workarounds.
How insurance classifies GLP-1s
Insurance plans treat GLP-1s as three distinct things depending on indication:
1. Type 2 diabetes drug (Ozempic, Mounjaro, Rybelsus, Trulicity) — broadly covered on almost every commercial plan, Medicare Part D, and most state Medicaid programs. 2. Chronic weight management drug (Wegovy, Zepbound, Saxenda, Wegovy Pill) — covered on roughly 60% of commercial plans; excluded by Medicare Part D statute; Medicaid coverage varies by state. 3. Cardiovascular risk reduction drug (Wegovy, via its 2024 SELECT-based indication) — a narrow but newly important pathway. Some Medicare Part D plans cover Wegovy for this indication even though they can't cover it for obesity.
The same drug can be covered for one indication and denied for another on the same plan. The ICD-10 code on your prescription matters more than any other single factor.
How to check your specific plan
Step 1 — find your formulary. Log into your insurance portal → "Benefits" → "Prescription drug list" or "Formulary." Search the brand name (Wegovy, Zepbound, etc.).
Step 2 — read the tier + PA requirements. A drug can be on formulary but require prior authorization (PA), step therapy, or quantity limits. All three are common for GLP-1s.
Step 3 — check the exclusion list. Some plans cover GLP-1s for diabetes only. The exclusion list (often in the back of the formulary PDF) will list "anti-obesity medications" or "weight management drugs" if excluded.
Step 4 — call the number on your card. Ask: "Is Wegovy covered on my plan for obesity? What's the PA requirement? What's my copay tier?" Get the answer in writing when possible.
Prior authorization: what your PA packet needs
Most commercial plans require PA for Wegovy, Zepbound, Saxenda, and the Wegovy Pill. A typical PA packet documents:
- BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition
(hypertension, type 2 diabetes, dyslipidemia, sleep apnea, CVD).
- A documented prior weight-loss attempt (usually 3–6 months of
diet/exercise, sometimes with a specific program required).
- No contraindications (personal/family history of medullary thyroid
carcinoma or MEN 2, history of pancreatitis in some plans).
- Prescriber attestation of diet and physical activity counseling.
PA success rates vary widely by prescriber. Telehealth programs like [program:mochi-health], [program:form-health], and [program:plushcare] submit hundreds of PAs per month and their approval rates typically exceed individual physicians'. Peer-to-peer reviews overturn about 40% of denials in the obesity-drug category.
Medicare: the Part D problem and the CV workaround
Medicare Part D is statutorily barred from covering "weight loss" drugs under Section 1860D-2(e)(2) of the Medicare Modernization Act.
Two paths exist for 2026 Medicare patients:
1. Wegovy for cardiovascular risk reduction. After SELECT and Wegovy's 2024 label expansion, CMS clarified that Part D plans may cover Wegovy for the CV indication in patients with obesity and established cardiovascular disease. Implementation has been gradual — not every Part D plan added it immediately. If you're on Medicare with CVD, call your Part D plan to ask specifically about the "cardiovascular risk reduction indication for Wegovy."
2. Treat and Reduce Obesity Act (TROA). Legislation to remove the Part D exclusion has been reintroduced in Congress repeatedly since 2013. It has not passed.
For Medicare patients without CVD, cash via LillyDirect Self Pay ($349/mo for Zepbound) or compounded programs is usually the most practical route.
Medicaid: a state-by-state patchwork
State Medicaid coverage for GLP-1s in obesity (as of Q1 2026):
Covers with PA: California, New York, Pennsylvania, Michigan, Minnesota, Massachusetts, New Jersey, Washington, Oregon, Illinois, Virginia, North Carolina, Delaware, Rhode Island, Maryland.
Does not cover or restrictive criteria: Texas, Florida, Georgia, Tennessee, Alabama, Mississippi, Louisiana, Missouri, Kansas, Arizona, Oklahoma, Arkansas, South Carolina, Kentucky, Indiana, Ohio, Iowa, Nebraska, North Dakota, South Dakota, Wyoming, Idaho, Nevada, Utah, Montana.
Mixed / MCO-dependent: Colorado, New Mexico, Wisconsin, West Virginia, Maine, New Hampshire, Vermont, Connecticut, Hawaii, Alaska.
Always verify with your specific Medicaid managed care organization — plan names and formularies change annually. [program:mystart-health] specializes in Medicaid activation.
Employer self-funded plans: the hidden variable
Roughly two-thirds of Americans with employer-sponsored insurance are covered by self-funded plans, where the employer — not the insurance company — decides whether GLP-1s are on formulary. This is why two co-workers at different companies with the same "Aetna card" can have radically different coverage.
If your employer is considering dropping GLP-1 coverage, HR's decision matters more than anything you can do individually. Employee advocacy (surveys, benefits comments) shifts this more than most people realize.
When coverage is denied: your options
1. Appeal the denial. Work with your prescriber to submit an appeal with additional clinical documentation. Peer-to-peer review with the plan's medical director overturns about 40% of obesity-drug denials. 2. Switch to a covered alternative. If Zepbound is denied, Wegovy may be covered (or vice versa). If both are denied for obesity, ask about Ozempic coverage for diabetes if applicable. 3. Manufacturer cash programs. LillyDirect Self Pay at $349/month for Zepbound and NovoCare Pharmacy at $499/month for Wegovy are the lowest brand-name cash prices in the U.S. market. 4. Compounded alternatives. Identical-molecule compounding ended after FDA shortage-list removal in 2024–2025. Remaining options are non-identical analogs of uncertain equivalence. [program:trimrx] and a handful of others continue to offer these at $99–$199/month. 5. Savings cards. Even when your plan denies, the Zepbound and Wegovy Savings Cards can take list prices down to ~$500–$650/month — worth checking before paying cash.
Cost snapshot (April 2026)
| Scenario | Zepbound | Wegovy | Ozempic | Saxenda | |---|---|---|---|---| | Commercial, covered, with card | $25 | $0–25 | $25–100 | $25–60 | | Commercial, not covered | $349 | $499 | $999 | $299–499 generic | | Medicare Part D (obesity) | No | No | — | No | | Medicare Part D (CVD + obesity) | No | Some plans | — | No | | Medicare Part D (diabetes) | — | — | Yes | — | | Cash direct from manufacturer | $349 | $499 | $499 diabetes | — |
What to do next
Run the [tool:matcher] to get a ranked view of your cheapest paths given your specific insurance, goals, and drug preferences. Coverage rules change every plan year — we update this guide quarterly as formularies, state Medicaid rules, and Medicare guidance shift.